Cancer screening company faces tough IPO test as market cools
Ammunition Life-tech has commercially launched five diagnostic tests for various types of cancer but could struggle to win over investors at an elevated valuation Key Takeaways: The company’s combined losses…
Recent Articles
RELATED ARTICLES
-
After winning global EV crown, BYD faces new challenge with profitability test
002594.SHE - Jacobio Pharma poised to turn a profit from precision cancer drugs
- Will yet another silicon carbide IPO test investor patience?
-
Lotus profit metrics improve, but road ahead still looks tough
LOT.US
- From friends to foes: Agile faces mounting troubles from former partner
